Showing 4,141 - 4,160 results of 5,404 for search '(( significant decrease decrease ) OR ( significant factor decrease ))~', query time: 0.42s Refine Results
  1. 4141

    Table_4_Temperature affects major fatty acid biosynthesis in noug (Guizotia abyssinica) self-compatible lines.DOCX by Adane Gebeyehu (12527500)

    Published 2024
    “…</p>Conclusion<p>The study suggests a significant contribution of genotype to the variation in seed setting and environmental factors (mostly temperature) to the oleic acid content. …”
  2. 4142

    Data Sheet 1_Correlation between cortical morphology and synaptic-associated proteins levels in poststroke aphasia: a pilot study.docx by Yun Cao (111731)

    Published 2025
    “…Correlation analysis was conducted among factors with significant group differences.</p>Results<p>Compared with HCs, PSA patients had significantly altered serum levels of α-SYN, BDNF, TrkB, CREB, and GAP-43. …”
  3. 4143

    Table 1_Trends in diet structural composition and quality among adults in Beijing, China (2010–2022).docx by Ningsu Chen (18014155)

    Published 2025
    “…Background<p>Unbalanced dietary patterns are a major risk factor for chronic non-communicable diseases. Examining trends in population-level dietary structural composition and quality is essential for monitoring nutritional transitions, identifying key dietary risks, and developing targeted public health policies.…”
  4. 4144

    Image3_A novel functional IKBKE variant activating NFAT in a patient with polyarthritis and a remittent fever.jpeg by Saeko Yamada (11899439)

    Published 2024
    “…She had a poor response to corticosteroids or disease-modifying antirheumatic drugs, including the tumor necrosis factor-α antagonist, etanercept, and the anti-interleukin-6 receptor antibody, tocilizumab.…”
  5. 4145

    DataSheet1_A novel functional IKBKE variant activating NFAT in a patient with polyarthritis and a remittent fever.docx by Saeko Yamada (11899439)

    Published 2024
    “…She had a poor response to corticosteroids or disease-modifying antirheumatic drugs, including the tumor necrosis factor-α antagonist, etanercept, and the anti-interleukin-6 receptor antibody, tocilizumab.…”
  6. 4146

    Table 2_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…Similarly, rheumatoid factor (RF) levels significantly decreased after treatment (MD = −318.20,95%CI:−364.66,−271.73) and remained low at the 6-month follow-up (MD = −287.78, 95%CI:−511.58,−63.97).…”
  7. 4147

    Table 4_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…Similarly, rheumatoid factor (RF) levels significantly decreased after treatment (MD = −318.20,95%CI:−364.66,−271.73) and remained low at the 6-month follow-up (MD = −287.78, 95%CI:−511.58,−63.97).…”
  8. 4148

    Supplementary file 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…Similarly, rheumatoid factor (RF) levels significantly decreased after treatment (MD = −318.20,95%CI:−364.66,−271.73) and remained low at the 6-month follow-up (MD = −287.78, 95%CI:−511.58,−63.97).…”
  9. 4149

    Table 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…Similarly, rheumatoid factor (RF) levels significantly decreased after treatment (MD = −318.20,95%CI:−364.66,−271.73) and remained low at the 6-month follow-up (MD = −287.78, 95%CI:−511.58,−63.97).…”
  10. 4150

    Table 3_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…Similarly, rheumatoid factor (RF) levels significantly decreased after treatment (MD = −318.20,95%CI:−364.66,−271.73) and remained low at the 6-month follow-up (MD = −287.78, 95%CI:−511.58,−63.97).…”
  11. 4151

    Image1_A novel functional IKBKE variant activating NFAT in a patient with polyarthritis and a remittent fever.jpeg by Saeko Yamada (11899439)

    Published 2024
    “…She had a poor response to corticosteroids or disease-modifying antirheumatic drugs, including the tumor necrosis factor-α antagonist, etanercept, and the anti-interleukin-6 receptor antibody, tocilizumab.…”
  12. 4152

    Image2_A novel functional IKBKE variant activating NFAT in a patient with polyarthritis and a remittent fever.jpeg by Saeko Yamada (11899439)

    Published 2024
    “…She had a poor response to corticosteroids or disease-modifying antirheumatic drugs, including the tumor necrosis factor-α antagonist, etanercept, and the anti-interleukin-6 receptor antibody, tocilizumab.…”
  13. 4153

    Table_1_Associations between metabolic score for visceral fat and adult lung functions from NHANES 2007–2012.docx by Jiacai Zhou (20325867)

    Published 2024
    “…Background<p>Obesity is a significant part of the factors affecting lung function, and the assessment of obesity using the Metabolic Score for Visceral Fat (METS-VF) is more precise than other indicators like waist circumference and body mass index. …”
  14. 4154

    Data Sheet 1_Association between serum 25-hydroxyvitamin D concentrations and platelet to high-density lipoprotein cholesterol ratio: evidence from two population-based studies.doc... by Ming Wang (172316)

    Published 2025
    “…Specifically, for every 1-unit increase in 25(OH)D, PHR decreased by 0.23 to 0.41 units across models. This association remained significant when comparing the highest quartile (Q4) to the lowest quartile (Q1) of 25(OH)D, with PHR decreasing by 14.84 to 27.65 units across models. …”
  15. 4155

    Data Sheet 3_Comparative effectiveness of various combined interventions for type 2 diabetes and obesity: a systematic review and network meta-analysis.docx by Li Cui (37567)

    Published 2025
    “…Addressing obesity, a key factor in T2DM, through exercise can improve metabolic health and reduce inflammation. …”
  16. 4156

    Data Sheet 1_In silico molecular studies of Phosphinogold(I) thiocarbohydrate complexes: insights into multi-target anticancer mechanisms.docx by Alkhair Adam Khalil Mohamed (21529289)

    Published 2025
    “…Complex 13 demonstrated high in vitro activity against prostate, colon, and breast cancer cell lines (IC50 = 0.03, 0.25, and 0.07 μM respectively), collaborating with a significant interaction with Human Epidermal Growth Factor Receptor 2 (HER2) (–71.15 kcal/mol binding affinity) in silico. …”
  17. 4157

    DataSheet1_Shenshuaikang enema restores the intestinal barrier and microbiota-gut-kidney axis balance to alleviate chronic kidney disease via NF-κB pathway.docx by Yan Ye (549400)

    Published 2025
    “…</p>Results<p>We found that SSKE improves renal function, attenuates renal fibrosis, reduces inflammatory factor levels, and decreases damage to intestinal and renal structures in adenine-induced CKD rats. …”
  18. 4158

    Table 1_Effect of ticagrelor combined with metoprolol extended-release tablets on cardiac function and clinical prognosis in elderly patients with acute coronary syndrome after per... by Lili Wang (104605)

    Published 2025
    “…Additionally, it effectively increases myocardial injury markers and reduces serum inflammatory factor levels.</p>…”
  19. 4159

    DataSheet1_Effects of inulin-type oligosaccharides (JSO) from Cichorium intybus L. on behavioral deficits induced by chronic restraint stress in mice and associated molecular alter... by Caihong Yao (15344128)

    Published 2024
    “…Histological and molecular analyses revealed that JSO treatment attenuated neuronal loss in the hippocampus (Hip) and medial prefrontal cortex (mPFC) and reduced the expression of inflammatory markers such as Iba-1 and GFAP in these regions. JSO significantly downregulated the mRNA and protein expression of pro-inflammatory factors (IL-1β, TNF-α, IL-6) while increasing anti-inflammatory markers (IL-10, TGF-β) (P< 0.05). …”
  20. 4160